

Bill Summary
1st Session of the 59th Legislature

Bill No.:	SB 513
Version:	HASB
Author:	Sen. Rosino
Date:	05/19/2023

Bill Analysis

SB 513 requires each health benefit plan to provide coverage for biomarker testing and to provide evidence of such coverage. The document showing the plan covers biomarker testing shall include labeled indications for tests that are approved or cleared by the United States Food and Drug Administration (FDA), tests for a drug that is approved by the FDA, precautions on FDA approved drug labels, national coverage determinations or Medicare administrative contractor local coverage determinations, and nationally recognized clinical practice guidelines and consensus statements. The insured shall also have access to a clear, readily available, and convenient process to request an exception to a coverage policy of a health benefit plan under this subsection.

House Amendments

HA's to SB 513 defines "clinical utility" as it relates to the provisions of this measure and requires treatment decisions to provide clinical utility.

Prepared by: Kalen Taylor